How to Get Prescribed Compounded Tirzepatide in 2026

On February 18, 2025, the FDA's enforcement window for mass-compounded tirzepatide closed. Compounded tirzepatide is still legal, but only for patients with documented medical necessity through a 503A state-licensed pharmacy.

That single shift changed who can get a prescription, what it has to say, and what you'll pay. The shortage list ended December 19, 2024. The 503B outsourcing deadline followed on March 19, 2025, and a federal court upheld the FDA on May 7, 2025 in Outsourcing Facilities Association v. FDA — the same regulatory arc that produced the Lilly v. Henry Meds litigation.

Three real pathways remain: a documented allergy to an inactive ingredient like polysorbate 80, a sub-2.5mg dose that doesn't exist in any commercial product, or a combination formulation with a clinical purpose (tirzepatide plus B6 or niacinamide). If one of those describes you, how to get prescribed compounded tirzepatide is a clear seven-step process. If none do, the honest answer is a different prescription, not a different intake form.

Here's how the process actually works in 2026.

Step 1: Confirm You Medically Qualify

Before anything else, the math. The FDA-approved indication for tirzepatide (Zepbound) is BMI 30 or higher on its own, or BMI 27 to 29.9 with at least one weight-related condition.

If you're in the 27 to 29.9 range, document one of the following:

  • Hypertension
  • Dyslipidemia (high cholesterol)
  • Type 2 diabetes
  • Obstructive sleep apnea
  • Cardiovascular disease
  • PCOS
  • Fatty liver disease (MASH or NAFLD)

PCOS isn't on the Zepbound label verbatim, but it's recognized in clinical practice and accepted by most legitimate telehealth prescribers. A 38-year-old woman with BMI 28 and a documented PCOS diagnosis qualifies, full stop. So does someone with BMI 28 and untreated obstructive sleep apnea, even if the sleep study was last year. Many BMI-27 patients carry an unrecognized comorbidity. Screening for sleep apnea, fatty liver, or dyslipidemia before assuming you don't qualify is worth a primary care visit.

The contraindication list is short and absolute. Telehealth intake forms screen for all of these:

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • Pregnancy or active planning
  • History of pancreatitis
  • Severe gastroparesis

A BMI of 25 to 26.9 with no comorbidity does not qualify on label. Some platforms will prescribe anyway. We don't recommend it. The 65% appeal-overturn rate on Zepbound prior authorizations applies to people who actually meet the indication, and a lower-BMI prescription weakens that record.

Best fit: BMI 30 or higher, or BMI 27 plus at least one of the named conditions. Skip if: you have an MTC family history, are pregnant or planning, or have a pancreatitis history. Those are non-negotiable.

Step 2: Understand the 503A Personalization Exception

The shortage ending didn't kill compounded tirzepatide. It killed mass-compounded tirzepatide. Those are different things, and the difference is what makes a legal 2026 prescription possible.

Two pharmacy categories matter here. A 503B outsourcing facility produces large bulk batches for clinics and platforms without individual prescriptions. As of March 19, 2025, 503B facilities cannot legally compound tirzepatide. The federal court ruling on May 7, 2025 closed the appeal route. A 503A pharmacy, by contrast, is state-licensed and fills patient-specific prescriptions, one script at a time, when the prescriber documents that the commercial product cannot meet a particular individual need. That door is still open.

There are four real 503A justifications a prescriber can document:

  1. Documented allergy to an inactive ingredient. Polysorbate 80 is the most cited. A 2024 case report describes a 67-year-old patient with a biphasic anaphylactic reaction to tirzepatide, hypotensive enough to require ICU admission. True polysorbate 80 hypersensitivity is rare, but when an allergist documents it, a 503A pharmacy can fill a polysorbate-free formulation.
  2. A dose not commercially available. Zepbound pens start at 2.5mg. Anything below that (1.0mg, 1.5mg, 1.8mg weekly) does not exist in any FDA-approved product, and a custom sub-2.5mg dose is by definition commercially unavailable.
  3. A different route. Oral or sublingual tirzepatide for patients with documented injection issues.
  4. A combination formulation with a clinical purpose. Tirzepatide plus pyridoxine (B6) for nausea management is the most clinically defensible — see our deep dive on why your compounded tirzepatide has B6, B12, or niacinamide. Tirzepatide plus niacinamide is the formulation Empower Pharmacy openly offers in its 17mg/mL plus 2mg/mL niacinamide configurations.

The legal weight sits on the prescriber and pharmacy, not on you. Per the FDA's own framing, the rules don't directly prohibit physicians from ordering compounded tirzepatide. They require the prescriber and 503A pharmacy to ensure the personalization meets the standard.

What disqualifies a script: cost savings alone. Anyone telling you "we compound it because it's cheaper" is operating in a gray zone. Regulatory expert Martha Rumore has flagged the "essentially a copy" rule plainly: same active ingredient, dose strength within 10%, same route as Zepbound is prohibited regardless of shortage status. Your prescription has to specify a real personalization.

If you fit one of these four boxes, a 503A pharmacy can legally fill your script. If you don't, it can't, and any platform that says otherwise is taking a risk you don't want to be downstream of.

Step 3: Choose a Legitimate Telehealth Provider

A patient named Laura Franzese spent $1,000 on a bulk tirzepatide order from Zappy. The vials arrived with Ousia labels, and she found out on Reddit that her pharmacy may not have been licensed at all. That's the pattern you're trying to avoid, and the verification takes about ten minutes.

Two checks, not one. Verify the platform AND verify the pharmacy. They're separate.

The lookup tools to use:

Before paying, ask the platform four questions:

  1. What is the name of the specific 503A compounding pharmacy filling my script?
  2. Can I see the Certificate of Analysis (COA) for my batch?
  3. Is the formulation tirzepatide base form, not tirzepatide sodium or tirzepatide acetate?
  4. Is the API supplier on the FDA Import Alert list?

Legitimate platforms answer all four without flinching. Empower Pharmacy, for example, is PCAB-accredited and operates both 503A and 503B facilities openly. When a platform refuses to name the pharmacy, that's the answer.

Red flags worth memorizing:

  • Product labeled "for research purposes only" or "not for human consumption"
  • No prescriber involvement, no medical evaluation
  • Plain vial with no pharmacy label, no lot number
  • Prices below $2/mg (under $80/month)
  • Vendor based overseas, ships from China
  • In-house HPLC purity test only, no sterility or endotoxin testing

The supply-chain stakes are real. Between March and August 2025, the Partnership for Safe Medicines tracked 120 kilograms of tirzepatide labeled "for compounding" arriving from unregistered Chinese facilities. One 10-kilogram shipment alone (roughly 4 million starting doses) came from a single Chengdu manufacturer the FDA added to the import alert list on July 3, 2025.

The September 2025 FDA enforcement wave clarified the legitimate field further. The agency issued 55-plus warning letters in a single window, including two to Hims & Hers. Some platforms quietly stopped offering tirzepatide. Others kept going on personalization arguments — the Lilly v. Henry Meds case is testing where that line actually sits. Verifiable accreditation is how you tell which is which.

Quick comparison: a legitimate platform names its pharmacy, provides a COA on request, and matches an accreditation lookup. A gray-market vendor has no prescriber, no label, no accreditation, and prices that don't add up.

Step 4: Complete the Intake Form Honestly

The intake form is where the legal path actually starts. Get this part right and the rest of the process moves on rails. Get it wrong and your prescription will sit unfilled, or worse, get filled by a platform that shouldn't have approved it.

Every legitimate intake (GobyMeds, TrimRx, Eden, NiceRx) asks for the same baseline:

  • Name, DOB, sex
  • Current medications and conditions
  • Allergies, including specific past reactions to Ozempic, Wegovy, Mounjaro, or Zepbound
  • Pregnancy or planning status
  • Contraindication screen: pancreatitis, MTC/MEN2, gastroparesis, insulin-dependent diabetes, gallstones, gastric bypass
  • Height, current weight, goal weight
  • Prior GLP-1 use within the past 4 weeks

Then comes the load-bearing question: why do you need a personalized formulation? Per Martha Rumore, that justification has to land on the prescription itself, not just the chart. Here's how to describe each of the four scenarios truthfully.

Inactive ingredient allergy. "I had [rash, swelling, anaphylaxis] after my last Mounjaro or Zepbound injection. My allergist worked up a reaction to polysorbate 80." Don't fabricate this. Prescribers should have the allergy documentation, and a fake answer puts both of you on shaky ground.

Sub-titration or microdose need. "I had severe nausea and vomiting on the 2.5mg starter dose and need a lower dose to titrate up." This is the most common pathway, and it's real. Dr. Craig Koniver's published microdosing protocol starts women at 1.5mg/week and men at 1.8mg/week, both below any FDA-approved dose. About 5 to 7% of Zepbound clinical-trial participants discontinued for GI side effects, and microdosing is the documented strategy to retain those patients.

B6 (pyridoxine) combination. "I have a documented history of severe GI side effects on GLP-1 medications and want a formulation that includes pyridoxine for nausea." The mechanism is established — full breakdown in our tirzepatide compound additives explainer. A pregnancy-nausea RCT found B6 at 25mg every 8 hours significantly reduced vomiting (8 of 31 patients vs 15 of 28 on placebo). NiceRx's typical formulation runs 50mg/mL B6, so a 0.1mL injection delivers about 5mg.

Inability to tolerate commercial dose increments. "The 2.5mg-to-5mg jump produced side effects I couldn't manage. I need an intermediate dose like 3.5mg." That's a real 503A justification because the 3.5mg dose doesn't exist commercially.

If none of the four describe you, the honest pathway is LillyDirect ($299 to $449/month) or an insurance appeal on Zepbound. The 65% appeal-overturn rate is real. Lying on an intake form doesn't open a pathway. It opens you to a denial after payment, which is exactly the TrimRx pattern flagged in their Trustpilot reviews: charged before approval, then fighting for a refund.

Tell the truth about your situation. The four pathways are real. If one of them describes you, say so plainly. If none do, the honest answer is a different prescription, not a different intake form.

Step 5: Review the Prescription and Formulation

You're approved. Before you pay, two minutes of reading saves a lot of regret.

A legitimate compounded tirzepatide prescription should show four things on the script itself:

  1. Patient-specific (your name, not a batch lot)
  2. Documented medical-necessity language (the specific 503A justification, written out)
  3. Specific concentration (mg/mL) and total volume
  4. Named compounding pharmacy

Confirm base form. Per FDA 503A standards, only base-form tirzepatide is acceptable. Salt forms (tirzepatide sodium, tirzepatide acetate) are treated as different active ingredients without established safety or efficacy data. If your label or paperwork says "tirzepatide acetate," ask before you pay. The pharmacy may be sourcing from API channels that don't meet the standard.

If you're getting a B6 or niacinamide formulation, confirm the concentration. Empower Pharmacy publishes 17mg/mL tirzepatide plus 2mg/mL niacinamide in 4mL, 2.5mL, and 2mL vials. NiceRx commonly runs 50mg/mL pyridoxine. If the concentration looks unfamiliar, ask the platform what a single therapeutic dose translates to in mL. You should have a written dose-conversion chart in hand before your first injection.

This matters because dosing errors are the dominant safety problem with compounded multidose vials. The FDA tracked 545-plus adverse event reports tied to compounded tirzepatide through July 2025, many traced to patients pulling the wrong volume. Across all tirzepatide, dosing-error reports rose from 1,715 in 2022 to 15,887 in 2024. Most are not catastrophic. Some required hospitalization — see our recognition framework for tirzepatide adverse events and the MedWatch reporting walkthrough if anything goes wrong. The fix is reading the chart twice and matching mg to mL the first time.

Run the "essentially a copy" check. Per Martha Rumore, if your prescription is the same active ingredient, dose strength within 10%, and same route as Zepbound, the pharmacy isn't allowed to fill it under 503A even with the shortage no longer in effect. Your prescription should specify a real personalization (a sub-2.5mg dose, a B6 combination, a polysorbate-free formula). If it just says "tirzepatide 5mg/mL injection," that's a flag.

Best fit: Your prescription names base-form tirzepatide, names a verifiable pharmacy, and specifies a personalization. Skip if: any of those three are missing. Ask the platform before you swipe the card.

Step 6: Compare Your Real 2026 Pricing Options

The price gap between compounded and branded narrowed in 2025. It didn't close. Here's what the four real options cost in mid-2026:

  • Compounded telehealth (503A): $200 to $450/month. GobyMeds 12-week starter bundle: $399 ($133/month effective). TrimRx: $259/month. Eden: $229 first month, $349/month ongoing. NiceRx: $250 to $350/month. See the full compounded tirzepatide cost breakdown for line-by-line pricing across providers.
  • LillyDirect Self Pay: $299/month for 2.5mg, $399 for 5mg, $449 for 7.5mg through 15mg. Requires 45-day refill adherence to maintain that pricing.
  • Branded Zepbound retail (no insurance, no program): roughly $1,086/month.
  • Branded Zepbound with insurance plus Zepbound Savings Card: as low as $25/month, capped at $1,950/year in savings. Medicare and Medicaid patients are excluded.
  • Gray-market peptide vendors: below $80/month. Skip every single one.

Hidden costs to factor in. Lab work runs $100 to $300 for the initial panel. Cash-pay consultations run $100 to $250. Injection supplies (syringes, alcohol prep, sharps disposal) add $5 to $15/month. Compounded platforms usually bundle the consultation; LillyDirect requires a separate prescriber visit.

Use HSA or FSA where you can. Compounded tirzepatide is HSA/FSA eligible when prescribed for a diagnosed condition (obesity, T2D, overweight with comorbidity). Request a Letter of Medical Necessity at your first consult. It does double duty: HSA/FSA documentation and proof of your 503A medical-necessity basis for pharmacy records. 2026 limits: HSA $4,400 individual, $8,750 family; FSA $3,400.

Run the insurance appeal in parallel. More than 65% of denied Zepbound prior authorizations are overturned on appeal when the patient submits the LMN, comorbidity history, and prior weight-loss attempts. Appeals take 2 to 3 weeks. Use LillyDirect or compounded coverage during that window if you don't want a gap.

The verdict: cheapest legitimate path is compounded with a microdose or B6 justification at $200 to $300/month. Most predictable path is LillyDirect Zepbound vials at $299 to $449/month. If you have weight-loss insurance coverage, branded Zepbound with the Savings Card can drop to $25/month and beats both.

Step 7: Receive, Store, and Inject

Most platforms quote four to seven days from approval to door. Plan around that.

The end-to-end timeline:

  • Day 0: Intake submitted
  • Day 0-1: Automated eligibility check
  • Day 1-2: Prescriber review (asynchronous or live video)
  • Day 2: Prescription sent to 503A pharmacy
  • Day 2-4: Pharmacy compounds and tests (sterility, endotoxin, potency)
  • Day 4-7: Cold-packed overnight shipping
  • Day 7-10: First injection

Specific platform breakdowns: TrimRx 4 to 8 days. GobyMeds 4 to 7 days. Eden 24 to 48 hours for prescriber review plus shipping. LillyDirect cash-pay arrives in under a week.

What's in the box: a multidose vial, syringes, alcohol prep pads, sharps disposal info, dosing chart. Refrigerate immediately at 36 to 46°F. Do not freeze. Most compounded formulations are stable 30 to 60 days refrigerated, out of light.

Injection technique is subcutaneous, into the abdomen or thigh, rotating sites weekly. Pull each dose carefully against the chart. The 545-plus adverse events the FDA tracked through July 2025 traced largely to multidose vial dosing errors, not to the medication itself.

What to expect from your first dose: nausea peaks 36 to 72 hours post-injection in the first few weeks. Diarrhea, if it happens, lands around days 4 to 6. Sulfur burps show up in 30 to 40% of users (rarely covered in clinical-trial summaries; reliably reported in community logs). Appetite drops noticeably by day 3 or 4. At a 2.5mg starter or microdose, side effects are usually mild and predictable — see our day-by-day tirzepatide side-effect timeline for the full pattern.

Refrigerate immediately. Inject the same day each week. Track side effects in a notes app for the first month. If anything serious happens (severe abdominal pain, vision changes, signs of allergic reaction), stop and message your prescriber the same day.

Frequently Asked Questions

I was on compounded tirzepatide before March 2025 and my provider stopped renewing. What now?

Four options. Find a 503A platform that documents medical necessity (one of the four pathways). Transition to LillyDirect Self Pay at $299 to $449/month. File an insurance appeal on Zepbound with a Letter of Medical Necessity (over 65% are overturned). Avoid gray-market peptide vendors entirely. Most former compounded patients land on LillyDirect within two weeks while their appeal processes.

Can I get compounded tirzepatide if my BMI is exactly 27 with no comorbidity?

Not legitimately. The FDA Zepbound label requires BMI 30 or higher, or BMI 27 plus at least one named condition (hypertension, dyslipidemia, T2D, OSA, cardiovascular disease, PCOS, MASH). Some platforms will prescribe anyway. That's gray zone. The honest path is screening for sleep apnea, dyslipidemia, or fatty liver. Many BMI-27 patients have one and don't know it yet.

Is microdosing tirzepatide actually a real thing or a marketing trick?

Real. Dr. Craig Koniver's protocol starts women at 1.5mg/week and men at 1.8mg/week, both below any FDA-approved dose. Clinicians use it for side-effect-sensitive patients and for those rebuilding tolerance after a break. There's no RCT data below 2.5mg; all protocols extrapolate from SURMOUNT-1 dose-response data. It works for many patients. It's not snake oil.

Can I switch from Zepbound to compounded tirzepatide?

Yes, if you have a documented medical necessity (severe side effects on commercial doses, polysorbate 80 reaction, need for B6 combination). No, if you only want to save money. Cost savings alone is not a 503A justification. Mild GI adjustment from formulation changes typically resolves within 1 to 2 weeks after the switch.

How much weight will I actually lose on compounded vs branded?

Real-world data from a Reddit aggregate of 2,400 progress posts: compounded users averaged 16.2% body weight loss at 6 months vs 19.1% for branded. The gap disappears when you control for dose consistency and storage compliance. Clinical trial peak (SURMOUNT-1) was 20 to 25% at maximum dose. Storage and dose accuracy matter more than compounded vs branded.

How long until I see results?

Appetite suppression in 3 to 7 days. Measurable weight loss by week 3 or 4. Most patients hit 5 to 10% by month 3 and 15 to 20% by month 6 if they titrate to therapeutic doses. Microdosers see slower curves and lower peaks but better tolerability and often better long-term adherence. The body responds to consistency, not intensity.

More from VST GLP-1 Safety